associated with a lethal outcome. Simulation studies showed that the efficacy of neonatal CVVHD is limited Background. Certain inborn errors of metabolism become manifest during the neonatal period by acute mainly by blood-flow restrictions.
of continuous haemofiltration and intermittent haemo-Supportive management of neonatal-onset metabolic derangement dialysis in neonatal metabolic crises has been suggested in several case reports [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . However, the experience crises is still limited, and studies correlating the efficacy A central venous catheter was placed immediately to ascertain of neonatal rescue treatment with clinical outcome are good hydration and high energy supplementation. All protein lacking. In this study, we evaluated continuous veno-intake was discontinued for the first 24 h. A hypercaloric venous haemodialysis (CVVHD) in comparison with parenteral nutrition with glucose at a rate of 20-25 g/kg/day PD in neonates with inborn errors of metabolism, and with insulin at a low rate (0.05-0.1 IU/kg/h), lipids evaluated potential effects of the dialysis modality on (1-2 g/kg/day) and electrolytes was infused. long-term patient outcome.
In patients with urea-cycle disorders, sodium benzoate was given intravenously at a loading dose of 250 mg/kg over 2 h followed by a maintenance infusion of 250 mg/kg/day. In addition, intravenous -arginine hydrochloride was administered at a starting dose of 2 mmol/kg within 2 h, followed
Subjects and methods
by continuous infusion of 2 mmol/kg/day. Subjects with PA received intravenous -carnitine at a dose of 200 mg/kg/day.
Patients Dialysis
The files of all patients with a biochemically proven inborn error of metabolism treated by dialysis for a first metabolic Between 1988 and 1993, peritoneal dialysis (PD) was crisis during the first 4 weeks of life at Heidelberg University primarily performed in patients with acute metabolic crises. Children's Hospital between January 1988 and December Stylet catheters were placed percutaneously 3-5 cm below 1997 were reviewed. Four patients with MSUD, three patients the umbilicus and midline in all patients. In one case, the with propionic acidaemia (PA), and five patients with urea-catheter was replaced due to non-function by a surgically cycle disorders (ornithine transcarbamylase deficiency inserted single-cuff Tenckhoff catheter. PD was started using (OTCD) (n=2); carbamylphosphate synthetase deficiency fill volumes of 15 to 30 ml/kg body weight (Table 2) . Dwell (CPSD) (n=2); argininosuccinate lyase deficiency (ASLD) times ranged from 30 to 60 min. Standard lactate-buffered (n=1)) were identified. solutions with glucose concentrations of 1.5 or 2.4% were Diagnosis of MSUD was confirmed by high plasma levels used. of leucine, isoleucine, valine and allo-isoleucine. The
Since 1993, haemodialysis was performed via doublediagnosis of PA was made by increased urinary excretion of lumen catheters (5 French diameter/6.4 cm length, Medical methylcitrate, propionylglycine, and other characteristic Components Inc., Harleysville, USA) usually inserted into a organic acids. In each case, the diagnosis was later confirmed femoral vein. A BM11 pump system was used for blood by studies of propionyl-CoA carboxylase activity in cultured circulation (Baxter Dialysetechnik, Ettlingen, Germany) in skin fibroblasts. Patients with CPSD were initially character-connection with a BM14 double-peristaltic pump unit for ized by increased glutamine and alanine and decreased controlling dialysis fluid flow. The integrated BM11/14 citrulline and arginine concentrations in plasma. Patients device, which became available in Germany in 1993, permits with OTCD were characterized by the same plasma amino the maintenance of stable extracorporeal circuits at blood acid pattern as found in CPSD but highly increased urinary flow rates down to 5 ml/min, and to pass dialysis fluid safely orotic acid excretion. In both CPSD and OTCD, the at very constant rates of up to 100 ml/min along the dialyser. diagnosis was subsequently confirmed by the assay of specific A bicarbonate-buffered electrolyte solution (HEP39, Braunenzyme activity in liver tissue. ASLD was characterized by Schiwa, Glandorf, Germany) was used as dialysis fluid. As increased argininosuccinic acid concentrations in plasma and shown in Table 3 , blood flow rates ranged between 10 and urine, and confirmed by enzyme studies in red blood cells.
30 ml/min, and dialysate flow rates of 1 to 5 l/h were chosen. The precise age and symptoms at initial presentation and Polysulphone dialysers (Spiraflo HFT02, filter surface area at start of rescue therapy, details regarding dialysis and 0.2 m2 (Bellco, Mirandola, Italy)) were used in five, cupramsupportive medical treatment applied as well as the clinical monium dialysers (AM03, 0.3 m2 (Asahi Medical, Frankfurt, and developmental status at last observation were recorded Germany)) in two patients. The total volume of the extra- (Tables 1-3) . Moreover, the time course of the blood concen-corporeal system was 35-40 ml; the system was prefilled in trations of toxic metabolites (i.e. leucine in MSUD and all cases with blood in order to minimize haemodynamic ammonia in urea-cycle disorders and PA) during dialysis effects of the extracorporeal circulation. Heparin was admintreatment was monitored by a median of 10 (range 5-25) istered as a priming bolus of 1500 IU/m2 followed by metabolite measurements per patient.
continuous infusion of 300-600 IU/m2/h. Anticoagulation was monitored by hourly assessments of the activated coagulation time with a target range of 120-150 s.
Laboratory measurements
Nutritional and medical management during Ammonia was determined in EDTA plasma using glutamate maintenance period dehydrogenase [21] . Plasma amino acids were measured by an automated ion-exchange chromatography with ninhyd-All patients received protein-restricted diets which were rine. Urinary organic acids were analysed by gas chromato-nutritionally complete and met the requirements of vitamins, graphy-mass spectrometry [22] . For the in vitro clearance energy, and trace minerals for growth and normal developstudy, leucine was measured by electrospray tandem mass ment. MSUD patients received a low-protein diet with reduced BCAA contents aiming at maintaining plasma spectrometry [23] . BCAA at near normal concentrations. To this end, a BCAA-of sodium benzoate at maximum doses of 250 mg/kg/day, and oral -arginine (100-200 mg/kg/day in CPSD and free amino-acid mixture (ILV-AM1/2 (SHS-Nutricia, Heilbronn, Germany) or MSUD1/2 (Milupa, Friedrichsdorf, OTCD, 400 mg/kg/day in ASLD), aiming at plasma arginine concentrations of 100-200 mmol/l. Treatment was monitored Germany)), was used as a supplement to the cowmilk-based formula diet. The diet was based on leucine requirements regularly, with target ranges of<80 mmol/l for plasma ammonia and <800 mmol/l for plasma glutamine. (300-400 mg/day); isoleucine (150-200 mg/day) and valine (240-280 mg/day) were provided in proportion. In patients with PA an amino-acid mixture free of precursor amino acids (threonine, methionine, valine, and isoleucine) (IMTV-CVVHD efficacy study AM1-3 (SHS-Nutricia) or OS1/2 (Milupa)) was prescribed to meet the recommended daily allowance. Furthermore, A simulation study was performed in order to evaluate the effects of blood and dialysate flow on the efficacy of ammonia carnitine was administered in oral doses of 100 mg/kg/day. In patients with urea-cycle defects, protein restriction was and leucine removal in the neonatal dialysis setting. To this end, the BM11/14 device was equipped with a neonatal tubing adjusted according to patient age and disease severity. Natural proteins were supplemented by an essential amino-system and the Spiraflo HFT02 dialyser (0.2 m2 surface area, BelIco, Mirandola, Italy). Two litres of an erythrocyte suspenacid mixture (E-AM1/2 (SHS-Nutricia) or UCD1/2 (Milupa)). Additional therapy included oral administration sion were mixed with 20% human albumin solution to 50% The dialysis modalities and efficacy of blood puribicarbonate and leucine were added to final ammonia and fication in the patients treated by CVVHD are given leucine concentrations of 1500 mmol/l. The blood mixture in Table 3 . The 50% metabolite reduction times were passed through the extracorporeal circuit into a drainage bag. significantly shorter with CVVHD than in the PD Blood flow was sequentially increased from 5 to 10, 15, 20, 30 group as a whole (P=0.048). The total duration of and 50 ml/min. This sequence was repeated at dialysate flows dialysis was also significantly shorter in the CVVHD of 1, 3, and 5 l/h. At each combination of blood and dialysate than in the PD group (P=0.015). A striking difference flow, blood samples were drawn from the inflow and the in dialysis efficacy was obvious in MSUD, where outflow lines after at least 120 ml had passed through the system plasma leucine concentrations dropped approximately to allow for equilibration. Ammonia and leucine clearances were calculated by the formula:
10-fold more rapidly in the patient undergoing CVVHD than in the three subjects treated by PD. The Clearance (ml/min)=blood flow (ml/min) * (C pre -C post )/C pre reduction of blood ammonia in hyperammonaemic where C pre and C post are the pre-and post-dialyser metabolite disorders appeared only slightly more efficient with blood concentrations.
CVVHD than with PD. The metabolite removal time was shortest in the two patients with the largest blood flow rates. In one patient on CVVHD (no. 5), blood Statistics ammonia levels reincreased to >200 mmol/l after termination of dialysis, so CVVHD was reinstituted 
in the dialyser was close to 100%. At higher blood where C is the blood metabolite concentration, t is the flows, extraction rates decreased and clearances became duration of dialysis in hours, and k is the elimination dependent on the dialysate flow rate.
coefficient. The time required to reduce the initial metabolite concentration by 50% was given by
Complications Non-parametric descriptive statistics were performed, In one case (no. 11) the haemodialysis catheter inserted using the Wilcoxon sign rank test to assess between-group via the right internal jugular vein perforated the right Table 1 , all patients developed symptoms
The haemodialysis procedure was generally well of disease, usually starting with poor feeding behaviour tolerated; no major haemodynamic alterations or signs and drowsiness, during the first week of life. A rapid of dysequilibrium were noted after start of blood deterioration of the neurological status followed, purification. One patient (no. 5) developed circulatory usually characterized by convulsions, somnolence, and failure 6 h after the start of haemodialysis in associcoma. In all but two cases, a metabolic disorder was ation with signs of bacterial sepsis, necessitating suspected shortly after onset of symptoms, and specific cardiopulmonary resuscitation for a short period. treatment was started within 1 week (median 3 days CVVHD was continued immediately after the event after first symptoms).
without any further complications. In the PD patients, obstruction and leakage of stylet catheters occurred in two cases each. In two patients Efficacy of dialysis the catheter had to be exchanged, once by another Metabolite blood concentrations were efficiently stylet and once by a Tenckhoff catheter. lowered by combined dialysis and supportive medical treatment in all patients.
PD was apparently more efficient in the two patients Clinical response with hyperammonaemia (50% ammonia reduction time 6.5 and 7.1 h) than in the three patients with MSUD Ten of the 12 patients showed clinical improvement shortly after start of dialysis. In these 10 patients, (50% leucine reduction time 16-36 h) (Table 2, Figure 1 ). In one hyperammonaemic patient, rapid spontaneous movements were usually observed after few hours of dialysis, and mechanical ventilation could initial reduction was obtained but due to septicaemia and ongoing catabolism, blood ammonia levels be stopped after a median of 2l h. Convulsions subsided in all except one MSUD patient who developed two remained between 120 and 200 mmol/l, necessitating maintenance PD for 4.5 days.
additional seizures even after normalization of blood leucine levels. One patient with OTCD (no. 8) did not patient with CPSD treated by PD (no. 10) showed episodes of bradycardia and hypotension, followed by show any clinical improvement despite normalization of blood ammonia levels, and all life-support treatment kidney and liver failure. In view of the disastrous clinical course, life support was stopped after 6 days was stopped on the 4th day of coma when clinical examination and EEG indicated brain death. Another of intensive care. monaemic coma in whom a 50% ammonia reduction time of less than 7 h was achieved survived with normal or moderately impaired neurodevelopment. In contrast, the four patients with a less rapid ammonia removal rate died either during the neonatal period or, with signs of severe retardation, during the later course of the disease. Notably, mean plasma ammonia concentrations at the start of treatment did not differ between survivors (1773 mmol/l ) and non-survivors (1908 mmol/l ). Similarly, the MSUD patient with the mildest neurodevelopmental impairment at last observation (no. 1) was the one with the most rapid leucine removal obtained by the use of CVVHD. While inborn errors of aminoacid and ketoacid metabolism have a relatively high prevalence and may manifest in the early neonatal period by lethal or Patient outcome permanently disabling metabolic crises, the diagnosis Of the 10 patients surviving the neonatal metabolic is frequently missed and few patients are referred to a crisis, two infants with urea-cycle defects died at 6 and specialized centre for life-saving emergency treatment 9 months of age after several periods of prolonged of their metabolic derangement. In consequence, the catabolism and metabolic derangement ( Table 1) . collection of 12 cases reported here represents one of Since both patients, one of whom was the one with a the largest single-centre experiences with neonatal history of pericardial tamponade and prolonged metabolic crises treated by dialysis published to date. resuscitation, were already severely developmentally Furthermore, we provide the first systematic clinical delayed, life-support measures were limited and no evaluation of the CVVHD technique in neonates, a further attempt at active toxin removal by dialysis treatment modality which has been suggested in animal was made. studies [24, 25] and in a single case report [19] to be Of the three patients with neonatal hyperammona-of superior efficacy compared to the conventionally emic crises due to PA, one showed completely normal used CVVH or PD. Finally, our study is the first to cognitive and motor development, and two had moder-correlate the efficacy of dialytic toxin removal with ate cognitive and/or motor deficits at the latest visit. long-term patient outcome. In all children, the course of disease was characterized by frequent episodes of metabolic derangement trig-Disorders causing neonatal metabolic crises gered by acute catabolic states, usually due to minor infectious illnesses. These episodes are either self-The most common forms of inborn errors of metabolism causing neonatal crises are MSUD, urea-cycle limited or responsive to intravenous energy and insulin administration.
disorders, and propionic acidaemia. MSUD is a disorder of branched-chain ketoacid degradation. All children with MSUD survived, but developed moderate to severe cognitive and/or motor retardation Particularly the accumulation of leucine and its metabolite, 2-ketoisocaproic acid, may cause acute brain during further follow-up. Recurrent seizures were observed in two children. An analysis of prognostic dysfunction [1] . While patients with MSUD usually survive the neonatal period and appear healthy indicators for patient survival revealed a striking association between the efficacy of dialytic toxin between episodes of metabolic imbalance, cognitive development is frequently subnormal. Propionic removal and outcome. The four patients with hyperam- [2] . While the severity of the defect may differ between patients, those presenting as neo-(25 ml/min) were achieved [19] . Consequently, dialytic efficacy was lower than in the case presented here; the nates with lethargy, feeding difficulties, and progressive encephalopathy have a high mortality rate, and severe reported 81% decrease achieved within 12 h was accomplished in less than 5 h in our setting. Still, neurological residua are frequent in survivors [5] . Hyperammonaemia is a constant finding in neonatal-Jouvet et al. [19] found CVVHD to be of superior efficacy compared to the CVVH and CVVHDF onset PA, and ammonia is regarded as the main toxic metabolite responsible for severe and irreversible ence-techniques applied in two other children with MSUD.
Blood flow limitations appear to determine the efficacy phalopathy. A paradigm for the deleterious effects of ammonia on the neonatal brain is given by patients of leucine removal by CVVHD in the neonate. Our in vitro simulation study (Figure 2) clearly demonstrates with urea-cycle disorders, who deteriorate rapidly with generalized muscular hypotonia, vasomotor instability, that the full potential of CVVHD is only utilized when adequate blood flow rates are achieved. hypothermia, and apnoea and, if left untreated, usually die in coma with cerebral or pulmonary haemorrhage [26 ] . Severe hyperammonaemia is common to all forms Dialysis efficacy in hyperammonaemic disorders of deficient urea synthesis. Ammonia induces various electrophysiological, vascular and biochemical altera-In hyperammonaemic metabolic crises, the use of PD was reported in eight articles on a total of 23 patients, tions which altogether explain the clinical features of hyperammonaemia [3, 27] . Because of the deleterious a continuous extracorporeal technique (mainly CVVH ) was applied in nine cases published in seven papers, effects of leucine and its toxic metabolites in MSUD and of ammonia in PA and urea-cycle disorders, and intermittent haemodialysis was used in 15 patients summarized in five reports. A survey of this body of efficient removal of these substances is considered crucial in the emergency management of neonatal literature suggests that PD is of limited efficacy in hyperammonaemic patients, with normalization of metabolic crises.
blood ammonia levels in no less than 24 h, continued dialysis requirements over 1-5 days on average, and a Dialysis efficacy in MSUD failure to decrease ammonia levels in individual cases [7, 8, 10, 11, 15, [29] [30] [31] . Better results were obtained using In patients with MSUD, the low endogenous clearance of leucine and other branched-chain keto-and amino continuous haemofiltration, by which blood ammonia was typically reduced by >90% within 10 h and which acids (BCAA) is insufficient to reverse the accumulation of BCAA that occurs during catabolic states. could be stopped within 24 h [12] [13] [14] [15] [16] [17] [18] . The most efficient toxin removal was achieved by the use of Since manifold higher BCAA clearance rates are achieved by PD, this technique has been regarded as intermittent haemodialysis, which reliably decreased blood ammonia concentrations by 75% within 3-4 h the method of choice since its introduction in the 1980s [8, 28, 29] . More recently, 100-150% higher BCAA [9] [10] [11] 18, 20] . However, repeated haemodialysis sessions were usually required because of residual or removal rates have been demonstrated experimentally with continuous extracorporeal blood purification rebound hyperammonaemia.
Hence, published literature confirms experimental techniques compared to PD [24] . In clinical practice, continuous arteriovenous [13] or venovenous haemo-findings [25] that ammonia is more efficiently removed by extracorporeal techniques than by PD. While filtration [16, 17, 19] , haemodialysis [19] , and haemodiafiltration [19] have been shown to be feasible, but the haemodialysis is more efficient than haemofiltration both in the experimental setting [25] and according to efficacy achieved in the clinical setting was only slightly higher in the four published case reports where leucine clinical observation, correction of hyperammonaemia may be delayed using intermittent HD due to postclearance was measured [1.7-4.4 ml/min) [13, 19] than in a single patient on PD whose leucine elimination dialytic rebound. Hence, efficacy considerations and the advent of the the BM 11/14, an integrated device rate was reported (0.9-3.4 ml/min) [28] . Also, the total duration of dialysis was only slightly shorter with specifically designed for extracorporeal blood purification in small children, prompted us to use CVVHD in extracorporeal (11-36 h [13, 16, 17, 19] ) than with PD (15-72 h [8,28,29] ). In contrast, an exceptional leucine neonates presenting with hyperammonaemic crises. Up to now, six patients have been treated using this clearance (60 ml/min) with a 46% decrease of plasma leucine levels within 3 h was reported in a single case technique. Hyperammonaemia was successfully corrected in all patients; a minor rebound occurred in using intermittent haemodialysis [20] .
In the MSUD patients presented here, the efficacy one case only. The rate of ammonia removal was satisfactory (>50% decrease within 12 h) in five of the of PD was comparable to the published findings, with a 50% leucine reduction time of 16-36 h, and a total six patients. The efficacy of toxin removal was better than that reported in literature for PD and comparable dialysis duration of 72-88 h. A markedly faster leucine elimination (50% reduction within 2.1 h) was obtained to that of continuous haemofiltration techniques, but lower than reported for intermittent haemodialysis. It in a patient treated by CVVHD. Optimal technical conditions for CVVHD, with high blood and dialysate should also be mentioned that the ammonia removal rates obtained by PD in two patients was in the same flow rates, were established in this patient. In the only range as with CVVHD. Our simulation study demon-neurological deficits in 26 patients with urea-cycle disorders surviving the first year of life. Cognitive strates that in the given dialysis setting, ammonia clearance is a linear function of blood flow until blood performance was closely related to the duration of neonatal hyperammonaemic coma but not to the peak flow rate exceeds 20 ml/min (Figure 2) . Hence, the small calibres of the catheters used (5 French double ammonia level. In keeping with the notion that the duration of neonatal hyperammonaemia is crucial for lumen) precluded a more efficient use of CVVHD. Of note, all previous reports on CAVH, CVVH, or patient outcome, the four patients in this study in whom a very rapid toxin removal was achieved by intermittent HD in neonates used 6.5 or 7 French double-lumen catheters or separate 5 and 8 French dialysis survived with no or moderate developmental impairment, whereas those with a slower detoxification single-lumen catheters in the umbilical vessels.
died either in the neonatal period or, with severe mental retardation, during further follow-up. In Complications of dialysis contrast, the initial blood ammonia concentration was not predictive of outcome, confirming the findings of The choice of a dialysis technique in neonates with metabolic crises is influenced not only by efficacy, but Msall et al. [4] .
With regard to the close relationship between the also by safety considerations and the expected rate of complications. In three of the five PD patients the use rate of toxin removal and outcome, our findings permit the conclusion that the most efficient dialysis modality of rigid stylet catheters was associated with obstruction and/or leakage, which required reduction of fill should be used in neonates with hyperammonaemic coma, irrespective of the risks of the technique. volumes, increase in inflow or outflow periods, and eventually exchange of the catheter, resulting in consid-Theoretical considerations and experimental results suggest that CVVHD should be the most efficient erable delays of efficient toxin removal. These problems are seen less frequently with Tenckhoff catheters [32] , dialysis modality for removing leucine and ammonia from the circulation; in our hands, its efficacy in which are now used in our unit. In CVVHD, vascular access was the greatest cause of concern. The use of neonates was mainly limited by blood flow restrictions caused by the use of small-lumen catheters. We therethe BM 11 blood pump permitted the use of 5 French double-lumen catheters, the smallest catheter size tech-fore recommend to use CVVHD as the first choice treatment in neonatal metabolic crises, taking care that nically suitable for neonatal dialysis. While the complication rate can be expected to decrease with a an adequately sized catheter is used. smaller catheter calibre and no major thrombotic complications or haemorrhages from the puncture site were Acknowledgements. The authors wish to thank D. Wittmer for expert technical help with the CVVHD simulation study. We also appreciate observed, the tragic case of a pericardial tamponade the excellent support of Drs A. Poege and D. Kohlmü ller in assaying points to the considerable risks still inherent in cen-blood ammonia and leucine. tral venous catheterization in critically ill neonates. Haemodynamic instability, another potential hazard of extracorporeal techniques in neonates, was efficiently References prevented by prefilling the system with blood and using appropriate extracorporeal tubing and dialyser
